Presented by
IVBM Event Coverage
Expanding the Role of PCSK9, SGLT2 Inhibitors in Cardiovascular Prevention: Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.
Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease.
Biomarker Testing Helps Guide Lung Cancer Therapy Selection: Stefanie Houseknecht, PharmD
Stefanie Houseknecht, PharmD, explains how oncology pharmacists support biomarker testing, targeted therapy selection, and patient education in lung cancer care.
Policy Changes, Faster Testing Turnaround Needed to Improve Precision Lung Cancer Care Access: Robert Kratzke, MD
Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.
Multidisciplinary Collaboration Advances Breast Cancer Care: Jennifer Sheng, MD
Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.
Pharmacists Help Navigate Precision Lung Cancer Care: Stefanie Houseknecht, PharmD
Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.
Consistent Follow-Up Strengthens Breast Cancer Survivorship Care: Jennifer Sheng, MD
Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.
Optimizing Biomarker Testing to Guide Early-Stage NSCLC Treatment: Robert Kratzke, MD
Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.
Reducing Coverage Barriers, Testing Delays Could Further Improve Lung Cancer Outcomes: Robert Kratzke, MD
Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care.
Pharmacy Workflows and Operational Readiness in Community Oncology: Jody Agena, PharmD
Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.
Oncology Pharmacists Bridge Research and Clinical Care: Minhee Kang, PharmD
Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.
3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD
Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.
Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD
Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.
Navigating Biomarker Testing in Early-Stage NSCLC: Robert Kratzke, MD
As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps when testing is negative for NSCLC.
The Expanding Frontier of Cardiometabolic Care
Clinicians gathered in Houston, Texas, to examine how newer drug options are reshaping cardiometabolic care and how integrated health systems can put evidence into practice.
The Unfinished Work of Value-Based Cancer Care
Ohio cancer care leaders identified persistent gaps in quality, pharmacy infrastructure, bispecific access, and biomarker testing at a May 2026 summit.
CAR T-Cell Therapy, Biomarkers, Clinical Trials, and Bladder Cancer Advances
Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.
Hayley Knollman, MD, Highlights Growing Role of Patient Preferences in Breast Cancer Care
Shared decision-making and quality of life are increasingly shaping metastatic breast cancer care amid persistent social barriers, notes Hayley Knollman, MD.
Patient-Centered Oncology Care, Guidelines, and Expertise Drive Value in Practice: Seungjean Chai, MD
At the IVBM Charlotte event, Seungjean Chai, MD, emphasized that patient-centered design, guidelines, and subspecialty expertise are essential to high-value oncology care.
Operationalizing BiTE Therapies in Community Oncology: Kaitlyn Schomberg, PharmD
Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings.
Multiple Myeloma Sequencing Evolves With CAR T, MRD Insights: Sylvester Homsy, MD
CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.
Access, Timing, Workflow Challenges Shape Biomarker Testing in NSCLC: Parth Desai, MBBS, MD
Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.
Decentralized Trials Hold Promise, but Cost, Infrastructure Challenges Remain: Arturo Loaiza-Bonilla, MD
Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.
Emerging Therapies in Multiple Myeloma Shift Focus Toward Cure: Asya Nina Varshavsky-Yanovsky, MD, PhD
New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.
Staging, ctDNA, and the Art of Personalizing Metastatic Breast Cancer Therapy: Hayley Knollman, MD
Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.
Shawn Davis, MD, on Access, Coverage, and the Future of Obesity Therapy
Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.
Building Trust, Not Just Enrollment: Amy Leader, DrPH, MPH, on Community Trial Success
Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.
Nurse Navigation, Reflex Testing Key to Closing Molecular Testing Gaps: Christopher D'Avella, MD
Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes
Lung Cancer Molecular Testing Nears 70%, Still Falls Short of Universal Use: Christopher D'Avella, MD
Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.
Shawn Davis, MD, on How Payers Should Think About Obesity Treatment Return on Investment
With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.
